October 23rd 2023
Sobuzoxane plus etoposide and rituximab may be safe and effective in a subgroup of elderly patients with diffuse large B-cell lymphoma and low tumor burden.
September 30th 2023
The biologic license application for odronextamab in relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma is based on data from the phase 1 ELM- 1 and phase 2 ELM-2 studies.
September 26th 2023
The conditional marketing approval of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma is based on data from the phase 1/2 EPCORE NHL-1 study.
September 11th 2023
Treatment with loncastuximab tesirine-lpyl in the safety run-in portion of the LOTIS-5 study appears to be promising, according to Michal Kwiatek, MD, PhD
July 16th 2023
Investigators of the LOTIS-9 trial are assessing loncastuximab tesirine plus rituximab for the treatment of unfit or frail patients with untreated diffuse large B-cell lymphoma.
European Commission Approves Glofitamab in Relapsed/Refractory DLBCL
Results from the phase 1/2 NP30179 trial led the European Commission to grant conditional marketing authorization to patients with relapsed/refractory diffuse large B-cell lymphoma.
NCCN Guidelines Support Epcoritamab Use in Diffuse Large B-Cell Lymphoma
Epcoritamab is a treatment option for patients with relapsed/refractory diffuse large B-cell lymphoma that was approved by the FDA based on findings from the phase 1/2 EPCORE NHL-1 trial.
Pembrolizumab/CAR T Therapy Shows Manageable Safety Profile in R/R DLBCL
The addition of pembrolizumab to tisagenlecleucel also appears to yield inconclusive efficacy signals and did not augment cellular expansion among patients with diffuse large B-cell lymphoma in a phase 1b study.
FDA Approves Polatuzumab Vedotin/R-CHP Combo in Previously Untreated DLBCL
Patients with previously untreated diffuse large B-cell lymphoma can now receive polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone following the FDA’s approval of the regimen.
EU’s CHMP Recommends Liso-Cel for Approval in R/R Large B-Cell Lymphoma
Findings from the phase 3 TRANSFORM study support the Committee for Medicinal Products for Human Use’s recommendation to approve lisocabtagene maraleucel for large B-cell lymphoma.
FDA ODAC Votes in Favor of Polatuzumab Vedotin in Previously Untreated DLBCL
Polatuzumab vedotin-piiq plus R-CHP was found to produce clinical efficacy in phase 3 POLARIX trial in patients with previously untreated diffuse large B-cell lymphoma, leading to an 11-to-2 vote from the FDA’s Oncologic Drug Advisory Committee.
Radiation Therapy in Diffuse Large B-Cell Lymphoma: A Little Boost Gets You Over the Finish Line
Bradford S. Hoppe, MD, MPH, and Omran Saifi, MD, offer a peer perspective on research by Gavin Jones, MD, and colleagues into radiation therapy in diffuse large B-cell lymphoma.
The Evolving Role of Radiation Therapy in DLBCL: From Early-Stage to Refractory Disease
Gavin Jones, MD, and colleagues explore the landscape of radiation therapy in diffuse large B-cell lymphoma.
Referral of Responders With Chemo-Sensitive Relapsed/Refractory DLBCL to HCT Associated With Improved OS
Referring responders with chemotherapy-sensitive relapsed/refractory diffuse large B-cell lymphoma who achieved a partial response or better to transplantation resulted in an improved overall survival vs those undergoing additional lines of therapy.
Rapcabtagene Autoleucel Shows Promise in Relapsed/Refractory DLBCL
Rapcabtagene autoleucel, a novel CAR T-cell therapy, was promisingly effective and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma, according to findings from a phase 1 dose-escalation study.
Atezolizumab With R-CHOP Shows Long-Lasting Activity in Previously Untreated DLBCL
Atezolizumab plus R-CHOP appeared to yield durable clinical benefit and a safety profile consistent with known toxicities in patients with previously untreated DLBCL, according to data from a phase 1b/2 trial.
Tafasitamab Plus Lenalidomide Improve Outcomes Vs Systemic Therapies in Relapsed/Refractory DLBCL
Tafasitamab plus lenalidomide prolonged overall survival compared with systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma, according to data from the retrospective RE-MIND2 study.
DLBCL Outcomes May be Predicted Using ctDNA as Prognostic Tool
Circulating tumor DNA levels could be a potential prognostic tool for predicting outcomes in diffuse large B-cell lymphoma.
Promising Efficacy Seen With Addition of Orelabrutinib to R-CHOP in Non-GCB DLBCL
In patients with non-germinal center B cell–like diffuse large B-cell lymphoma, the combination of orelabrutinib plus R-CHOP revealed an overall response rate of 86.4%.
Supplemental BLA Accepted by FDA for Polatuzumab Vedotin/R-CHP Combo for Previously Untreated DLBCL
Patients with previously untreated diffuse large B-cell lymphoma may benefit from treatment with polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone, for which a supplemental biologics license application was accepted by the FDA.
Relapsed or Refractory Diffuse Large B-Cell Lymphoma: “Dazed and Confused”
This review article written by Meghana Kesireddy, MBBS and Matthew A. Lunning, MD, reviews management and treatment of relapsed/refractory large B-cell lymphoma.
Tafasitamab Plus Lenalidomide Superior to Standard Therapies in Key Subgroups of High-Risk R/R DLBCL
Subgroup analysis of the RE-MIND trial support use of tafasitamab plus lenalidomide to treat high-risk diffuse large B-cell lymphoma.
Early Data Show Epcoritamab Induces Responses in High-Risk DLBCL in First Line
High response rates were noted in a phase 1/2 trial of the bispecific antibody epcoritamab to treat first-line, high-risk diffuse large B-cell lymphoma.
Current Frontline Treatment of Diffuse Large B-Cell Lymphoma
This review article discusses which frontline treatment are best for diffuse large B-cell lymphoma.
FDA Grants Regenerative Medicine Advanced Therapy and Fast Track Designations to C-CAR039 for Relapsed/Refractory DLBCL
A bi-specific anti-CD19/CD20 CAR T-cell therapy, C-CAR039, received a regenerative medicine advanced therapy designation and fast track designation from the FDA for treating patients with relapsed/refractory diffuse large B cell lymphoma.
Expert Commentary on the Product Profile of Loncastuximab Tesirine
In an interview with ONCOLOGY®, Keith Hecht, PharmD, offers a comprehensive review of real-world treatment considerations of loncastuximab tesirine as therapy for patients with diffuse large B-cell lymphoma.
Treatment With Tafasitamab, Lenalidomide, and R-CHOP Yields Promising Activity in Untreated DLBCL
Patients with previously untreated diffuse large B-cell lymphoma experienced promising responses after being treated with tafasitamab-cxix and lenalidomide plus rituximab, cyclophosphamide, doxorubicin, vincristin, and prednisone.
Favorable Efficacy and Safety Profiles Seen With YTB323 in Relapsed/Refractory DLBCL
YTB323 led to a promising safety profile and encouraging efficacy outcomes for adult patients with relapsed/refractory diffuse large B-cell lymphoma.
Progression-Free Survival Boost Noted With Polatuzumab Vedotin Plus R-CHP for Previously Untreated DLBCL
A 27% reduction in the risk of progression or death was noted when polatuzumab vedotin was added on R-CHP vs R-CHOP for patients with intermediate- or high-risk diffuse large B-cell lymphoma who received treatment in the first line.
Naratuximab Emtansine/Rituximab Yields Promising Responses in DLBCL
Treatment with naratuximab emtansine and rituximab appeared to be well-tolerated with efficacious responses in a population of patients with B-cell non-Hodgkin lymphomas who were ineligible for stem cell transplant or CAR-T cell therapy.
Addition of Ibrutinib to R-Mini-Chop for Newly Diagnosed DLBCL Shows Promise in an Elderly Population
Data presented at 2021 ASH indicate that 2-year progression-free survival rates were improved when ibrutinib was added to rituximab plus mini-CHOP in an elderly cohort of patients with previously untreated diffuse large B-cell lymphoma.
Tafasitamab and Lenalidomide Combo Yields Higher OS vs Standard Options in Relapsed/Refractory DLBCL
Patients with autologous stem cell transplant–ineligible relapsed/refractory diffuse large B-cell lymphoma appear to benefit from treatment with tafasitamab and lenalidomide.
Loncastuximab Tesirine Plus Ibrutinib in Relapsed DLBCL Trends Favorably at LOTIS-3 Interim Analysis
Anti-tumor activity coupled with a manageable safety profile was noted with the combination of ibrutinib plus loncastuximab tesirine for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma at an interim analysis of the LOTIS-3 trial presented at 2021 ASH.
Polatuzumab Vedotin/R-CHP Meets Primary End Point of Progression-Free Survival for DLBCL in POLARIX Phase 3 Trial
Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone helped patients to achieve a significantly improved progression-free survival over the standard of care for previously untreated diffuse large B-cell lymphoma.
Data Collected in Patients With DLBCL Reveal Real-World Trends for Use of Axi-Cel and Tisa-Cel
Real-world data regarding the use of tisagenlecleucel and axicabtagene ciloleucel CAR T-cell therapy are reported at 2021 EHA.
2 Clarke Drive Cranbury, NJ 08512